ICL Group Declares $0.04260 Cash Dividend, Payable September 17, 2025
ByAinvest
Wednesday, Aug 6, 2025 5:07 am ET1min read
EVGN--
The dividend amount is subject to change due to currency conversion from US dollars to New Israeli Shekels. ICL Group Ltd. has a dividend distribution policy that allows for a payout ratio of up to 50% of the annual adjusted net income [1].
This announcement comes after ICL Group Ltd. reported its second-quarter 2025 results, which included a significant increase in sales and a stable gross margin of 32% [2]. The company has also been actively seeking mergers and acquisitions (M&A) opportunities to expand its operations and market share [2].
ICL Group Ltd. has recently completed several strategic transactions, including the acquisition of the activity of Evogene's subsidiary, Lavie Bio, and the signing of joint venture agreements with Shenzhen Dynanonic to produce lithium iron phosphate for the European battery market [2].
References:
[1] https://investors.icl-group.com/stock-information/default.aspx
[2] https://www.marketscreener.com/news/icl-reports-second-quarter-2025-results-ce7c5ed9db81f724
ICL--
ICL Group Ltd. declared a cash dividend of $0.04260 per share, or $55 million. The dividend will be paid on September 17, 2025, to registered shareholders who own at least $2 worth of shares. The record date is September 3, 2025. The dividend amount is subject to change due to currency conversion from US dollars to New Israeli Shekels.
ICL Group Ltd. has announced a cash dividend of $0.0426 per share, equating to a total payout of $55 million. The dividend will be distributed to registered shareholders who own at least $2 worth of shares on the record date, which is set for September 3, 2025. The dividend payment is scheduled for September 17, 2025 [1].The dividend amount is subject to change due to currency conversion from US dollars to New Israeli Shekels. ICL Group Ltd. has a dividend distribution policy that allows for a payout ratio of up to 50% of the annual adjusted net income [1].
This announcement comes after ICL Group Ltd. reported its second-quarter 2025 results, which included a significant increase in sales and a stable gross margin of 32% [2]. The company has also been actively seeking mergers and acquisitions (M&A) opportunities to expand its operations and market share [2].
ICL Group Ltd. has recently completed several strategic transactions, including the acquisition of the activity of Evogene's subsidiary, Lavie Bio, and the signing of joint venture agreements with Shenzhen Dynanonic to produce lithium iron phosphate for the European battery market [2].
References:
[1] https://investors.icl-group.com/stock-information/default.aspx
[2] https://www.marketscreener.com/news/icl-reports-second-quarter-2025-results-ce7c5ed9db81f724
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet